PPARG and Epiphyses, Slipped: To our knowledge, there are no preclinical models of SCFE or Blount’s disease, but evidence from adult trials of PPARγ agonist rosiglitazone indirectly suggest that agonism of the PPARγ pathway results in decreased BMD and increased fracture risk.